RxDoctor Payments Data

Josephine Hwu, MD

Nephrology · Monterey Park, CANPI 1194170894

Payments from drug & device makers

$735in general payments, 2019–2025

Across 16 payments — averaging $45.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$295
  • AstraZeneca$125
  • Ardelyx, Inc.$100
  • Akebia Therapeutics Inc$87
  • Novartis$43
  • Vantive US Healthcare LLC$42
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$71697%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$735 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$228,436
Medicare patients
403
Services billed
2,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RenvelaSevelamer Carbonate13$20,544
LokelmaSodium Zirconium Cyclosilicate25$19,818
EntrestoSacubitril/Valsartan17$11,523
FarxigaDapagliflozin Propanediol14$11,384
JardianceEmpagliflozin13$9,686
JanuviaSitagliptin Phosphate12$9,501
DapagliflozinDapagliflozin Propanediol13$6,359
Sevelamer Carbonate18$2,777
Fluocinonide14$1,023
Calcium Acetate19$861
Nifedipine ErNifedipine20$715
Losartan Potassium44$416
Amlodipine Besylate58$325
Rosuvastatin Calcium21$286
Pantoprazole Sodium36$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$125$31,20239 claims
NovartisEntresto$43$11,52317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,341 nephrology providers in California.

Other nephrology in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →